ADDA

ADDA Biotech was a small private biotechnology company associated with patent filings in diabetes therapeutics. Publicly visible information is very limited, but patent records indicate the company worked on biopharmaceutical fusion proteins designed for diabetes treatment, including constructs combining an interleukin-1 receptor antagonist domain with incretin- or insulin-related receptor-binding components. The available evidence suggests a research-stage company rather than a clinically advanced developer, with no clear evidence of active clinical trials or commercial products. Corporate registry data indicate the California entity was dissolved, so the company does not appear to be active today.